Literature DB >> 16985756

Vaccine-based immunotherapy for prostate cancer.

S F Shariat, F Sadeghi, K M Slawin.   

Abstract

Entities:  

Year:  2000        PMID： 16985756      PMCID： PMC1476116     

Source DB:  PubMed          Journal:  Rev Urol        ISSN： 1523-6161


× No keyword cloud information.
  12 in total

1.  Phase II prostate cancer vaccine trial: report of a study involving 37 patients with disease recurrence following primary treatment.

Authors:  G P Murphy; B A Tjoa; S J Simmons; H Ragde; M Rogers; A Elgamal; G M Kenny; M J Troychak; M L Salgaller; A L Boynton
Journal:  Prostate       Date:  1999-04-01       Impact factor: 4.104

2.  Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer.

Authors:  M G Sanda; D C Smith; L G Charles; C Hwang; K J Pienta; J Schlom; D Milenic; D Panicali; J E Montie
Journal:  Urology       Date:  1999-02       Impact factor: 2.649

3.  Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer.

Authors:  J W Simons; B Mikhak; J F Chang; A M DeMarzo; M A Carducci; M Lim; C E Weber; A A Baccala; M A Goemann; S M Clift; D G Ando; H I Levitsky; L K Cohen; M G Sanda; R C Mulligan; A W Partin; H B Carter; S Piantadosi; F F Marshall; W G Nelson
Journal:  Cancer Res       Date:  1999-10-15       Impact factor: 12.701

4.  Follow-up evaluation of a phase II prostate cancer vaccine trial.

Authors:  B A Tjoa; S J Simmons; A Elgamal; M Rogers; H Ragde; G M Kenny; M J Troychak; A L Boynton; G P Murphy
Journal:  Prostate       Date:  1999-07-01       Impact factor: 4.104

5.  Follow-up evaluation of prostate cancer patients infused with autologous dendritic cells pulsed with PSMA peptides.

Authors:  B A Tjoa; S J Erickson; V A Bowes; H Ragde; G M Kenny; O E Cobb; R C Ireton; M J Troychak; A L Boynton; G P Murphy
Journal:  Prostate       Date:  1997-09-01       Impact factor: 4.104

6.  Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen.

Authors:  G Murphy; B Tjoa; H Ragde; G Kenny; A Boynton
Journal:  Prostate       Date:  1996-12       Impact factor: 4.104

Review 7.  Peptide and carbohydrate vaccines in relapsed prostate cancer: immunogenicity of synthetic vaccines in man--clinical trials at Memorial Sloan-Kettering Cancer Center.

Authors:  S F Slovin; H I Scher
Journal:  Semin Oncol       Date:  1999-08       Impact factor: 4.929

8.  Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: a phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease.

Authors:  G P Murphy; B A Tjoa; S J Simmons; J Jarisch; V A Bowes; H Ragde; M Rogers; A Elgamal; G M Kenny; O E Cobb; R C Ireton; M J Troychak; M L Salgaller; A L Boynton
Journal:  Prostate       Date:  1999-01-01       Impact factor: 4.104

9.  Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides.

Authors:  B A Tjoa; S J Simmons; V A Bowes; H Ragde; M Rogers; A Elgamal; G M Kenny; O E Cobb; R C Ireton; M J Troychak; M L Salgaller; A L Boynton; G P Murphy
Journal:  Prostate       Date:  1998-06-15       Impact factor: 4.104

10.  In vitro propagated dendritic cells from prostate cancer patients as a component of prostate cancer immunotherapy.

Authors:  B Tjoa; S Erickson; R Barren; H Ragde; G Kenny; A Boynton; G Murphy
Journal:  Prostate       Date:  1995-08       Impact factor: 4.104
View more
  2 in total

Review 1.  Trial Watch: Toll-like receptor agonists in cancer immunotherapy.

Authors:  Melody Smith; Elena García-Martínez; Michael R Pitter; Jitka Fucikova; Radek Spisek; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2018-10-11       Impact factor: 8.110

Review 2.  The Cellular and Molecular Immunotherapy in Prostate Cancer.

Authors:  Anirban Goutam Mukherjee; Uddesh Ramesh Wanjari; D S Prabakaran; Raja Ganesan; Kaviyarasi Renu; Abhijit Dey; Balachandar Vellingiri; Sabariswaran Kandasamy; Thiyagarajan Ramesh; Abilash Valsala Gopalakrishnan
Journal:  Vaccines (Basel)       Date:  2022-08-22
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.